Seer (SEER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Board unanimously rejected the revised unsolicited proposal from Radoff-JEC Group, citing it was not in the best interests of stockholders.
Confidence expressed in the company's strategy and growth opportunities, particularly in proteomics and AI-driven biology.
Ongoing business operations emphasized, with continued focus on customer delivery and platform advancement.
Forward-looking statements highlight plans, strategies, and capital deployment objectives, with caution regarding risks and uncertainties.
Voting matters and shareholder proposals
Proxy solicitation for the 2026 Annual Meeting will involve directors and certain executive officers as participants.
Stockholders will receive a definitive proxy statement and BLUE proxy card for voting.
Board of directors and corporate governance
Board members and executive officers involved in proxy solicitation are listed, with recent changes in their security holdings referenced.
Additional information on governance and compensation is available in prior proxy statements and SEC filings.
Latest events from Seer
- Board unanimously rejects revised unsolicited acquisition proposal; shareholder vote solicited.SEER
Proxy filing27 Apr 2026 - Board rejects acquisition proposal; proxy process for 2026 Annual Meeting initiated.SEER
Proxy filing27 Apr 2026 - Received unsolicited acquisition proposal and director nominations; board review underway.SEER
Proxy filing14 Apr 2026 - Acquisition proposal and board nominations prompt detailed review ahead of 2026 Annual Meeting.SEER
Proxy filing13 Apr 2026 - Strong growth, innovation, and new detector tech set the stage for future expansion.SEER
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 17% to $16.6M, with improved margins and a 67% increase in installed base.SEER
Q4 202526 Feb 2026 - Q2 revenue fell 23% to $3.1M; guidance cut, but cash remains strong and pipeline is growing.SEER
Q2 20242 Feb 2026 - High-impact publications and scientific validation drive optimism for growth in 2025.SEER
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Proteograph's robust, scalable platform accelerates unbiased biomarker discovery and scientific adoption.SEER
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026